Switch theme
Sign up to access all valuation multiples
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
2014
115
Last FY Revenue n/a
LTM EBITDA -$142M
$378M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ORIC Pharmaceuticals has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$142M.
In the most recent fiscal year, ORIC Pharmaceuticals achieved revenue of n/a and an EBITDA of -$142M.
ORIC Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ORIC Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$142M | XXX | -$142M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$145M | XXX | -$143M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$131M | XXX | -$128M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ORIC Pharmaceuticals's stock price is $8.
ORIC Pharmaceuticals has current market cap of $579M, and EV of $378M.
See ORIC Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $378M | $579M | XXX | XXX | XXX | XXX | $-1.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ORIC Pharmaceuticals has market cap of $579M and EV of $378M.
ORIC Pharmaceuticals's trades at n/a EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate ORIC Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ORIC Pharmaceuticals has a P/E ratio of -4.4x.
See valuation multiples for ORIC Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $579M | XXX | $579M | XXX | XXX | XXX |
| EV (current) | $378M | XXX | $378M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -2.6x | XXX | -2.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.4x | XXX | -4.5x | XXX | XXX | XXX |
| EV/FCF | -4.7x | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialORIC Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
ORIC Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ORIC Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ORIC Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ORIC Pharmaceuticals acquired XXX companies to date.
Last acquisition by ORIC Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . ORIC Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ORIC Pharmaceuticals founded? | ORIC Pharmaceuticals was founded in 2014. |
| Where is ORIC Pharmaceuticals headquartered? | ORIC Pharmaceuticals is headquartered in United States of America. |
| How many employees does ORIC Pharmaceuticals have? | As of today, ORIC Pharmaceuticals has 115 employees. |
| Who is the CEO of ORIC Pharmaceuticals? | ORIC Pharmaceuticals's CEO is Mr. Jacob M. Chacko, M.B.A.,M.D.. |
| Is ORIC Pharmaceuticals publicy listed? | Yes, ORIC Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of ORIC Pharmaceuticals? | ORIC Pharmaceuticals trades under ORIC ticker. |
| When did ORIC Pharmaceuticals go public? | ORIC Pharmaceuticals went public in 2020. |
| Who are competitors of ORIC Pharmaceuticals? | Similar companies to ORIC Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ORIC Pharmaceuticals? | ORIC Pharmaceuticals's current market cap is $579M |
| Is ORIC Pharmaceuticals profitable? | Yes, ORIC Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ORIC Pharmaceuticals? | ORIC Pharmaceuticals's last 12 months EBITDA is -$142M. |
| What is the current EV/EBITDA multiple of ORIC Pharmaceuticals? | Current EBITDA multiple of ORIC Pharmaceuticals is -2.7x. |
| What is the current FCF of ORIC Pharmaceuticals? | ORIC Pharmaceuticals's last 12 months FCF is -$80.5M. |
| What is the current EV/FCF multiple of ORIC Pharmaceuticals? | Current FCF multiple of ORIC Pharmaceuticals is -4.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
